MASKED IL12 PROTEIN

DE602023018741T2Active Publication Date: 2026-06-17TAGWORKS PHARAMCEUTICALS BV

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: DE · DE
Patent Type: Patents
Current Assignee / Owner: TAGWORKS PHARAMCEUTICALS BV
Filing Date: 2023-02-15
Publication Date: 2026-06-17

AI Technical Summary

Technical Problem

Existing methods for masking IL12 protein to minimize side-effects and control its activation at target sites are inefficient, relying on protease overexpression, have unnatural constructs, and risk off-target toxicity, with suboptimal EC50 ratios and unmasking kinetics.

Method used

IL12 proteins are modified with a Trigger moiety at lysine residues, allowing controlled activation by a separate activator molecule, independent of target site conditions, using diene/dienophile reactions to restore activity rapidly and selectively.

Benefits of technology

The solution provides masked IL12 proteins with reduced off-target effects, controlled unmasking kinetics, and improved EC50 ratios, minimizing anti-drug antibody responses and achieving targeted cytokine activity.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Need to check novelty before this filing date? Find Prior Art

No text content released.